# EDGAR Filing Document

**Accession Number:** 0000744452
**File Stem:** 0001104659-25-078611
**Filing Date:** 2025-8
**Character Count:** 25403
**Document Hash:** 6aba5b3622110dbf78c9f961dbdec6f0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-078611.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001104659-25-078611

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250814

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** APPLIED DNA SCIENCES INC
- **CENTRAL INDEX KEY:** 0000744452
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-TESTING LABORATORIES [8734]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 592262718
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36745
- **FILM NUMBER:** 251219410

**BUSINESS ADDRESS:**
- **STREET 1:** 50 HEALTH SCIENCES DRIVE
- **CITY:** STONY BROOK
- **STATE:** NY
- **ZIP:** 11790
- **BUSINESS PHONE:** 631-240-8800

**MAIL ADDRESS:**
- **STREET 1:** 50 HEALTH SCIENCES DRIVE
- **CITY:** STONY BROOK
- **STATE:** NY
- **ZIP:** 11790

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROHEALTH MEDICAL TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20010504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DCC ACQUISITION CORP
- **DATE OF NAME CHANGE:** 19990211

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DATALINK CAPITAL CORP/TX/
- **DATE OF NAME CHANGE:** 19980306

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

------

Date of Report (Date of earliest event reported): August 14, 2025

**Applied DNA Sciences, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br> (State or other jurisdiction<br> of incorporation) | **001-36745**<br> (Commission File Number) | **59-2262718**<br> (IRS Employer<br> Identification No.) |

---

**50 Health Sciences Drive**

**Stony Brook, New York 11790**

(Address of principal executive offices; zip code)

Registrant's telephone number, including area code:

**631-240-8800**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | APDN | The Nasdaq Stock Market |

---

**Item 2.02 Results of Operations and Financial Condition.**

On August 14, 2025, Applied DNA Sciences, Inc. (the "Company") issued a press release announcing its results of operations for the quarterly period ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(*d) Exhibits*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm2523531d1_ex99-1.htm) | [Press Release issued by Applied DNA Sciences, Inc. dated August 14, 2025 regarding results of operations for the quarterly period ended June 30, 2025.](tm2523531d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: August 14, 2025 | APPLIED DNA SCIENCES, INC. | APPLIED DNA SCIENCES, INC. |
|  | By: | /s/ Judith Murrah |
|  | Name: | Judith Murrah |
|  | Title: | Chief Executive Officer |

---

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm2523531d1_ex99-1.htm) | [Press Release issued by Applied DNA Sciences, Inc. dated August 14, 2025 regarding results of operations for the quarterly period ended June 30, 2025.](tm2523531d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2523531d1_ex99-1img001.jpg)

**Applied DNA Reports Third Quarter Fiscal 2025<br> Financial Results**

**STONY BROOK, N.Y.** – **August 14, 2025** - <u>Applied DNA Sciences, Inc</u>. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended June 30, 2025. The Company's Form 10-Q for its fiscal third quarter can be viewed on the <u>SEC Filings</u> page of its Investor Relations website. The Company will not host a conference call to discuss these results. Applied DNA investor relations remains available for questions at <u>investors@adnas.com</u>.

Following its previously announced recent restructuring and workforce reductions ("Corporate Actions"), the Company, through its majority-owned LineaRx, Inc. subsidiary, has transitioned to a pure play provider of synthetic DNA and mRNA manufacturing solutions for advanced biotherapeutics, such as gene therapies, personalized medicine, adoptive cell therapies, messenger RNA (mRNA) therapeutics, and DNA vaccines, as well as diagnostic applications that utilize chemically-modified DNA. The Company is commercializing three distinct and complementary technology solutions for DNA production:

&nbsp;&nbsp;&nbsp;&nbsp;· LineaDNA™:
 A proprietary, cell-free DNA production platform that uses a large-scale PCR process to rapidly
 and efficiently produce high-fidelity, synthetic DNA as a market-ready alternative to plasmid
 DNA (pDNA). LineaDNA is applicable to biotherapeutics development and production, serving
 as the starting material for mRNA therapeutics and vaccines and as a critical component in
 numerous *in vitro* diagnostics (IVDs).

&nbsp;&nbsp;&nbsp;&nbsp;· LineaRNAP™:
 A next-generation T7 RNA polymerase (RNAP) used to transcribe DNA into mRNA. Designed as
 a direct replacement for wild-type T7 RNAP currently utilized in conventional IVT mRNA systems
 that use synthetic or pDNA templates, LineaRNAP incorporates a patented DNA-binding domain
 that delivers high mRNA yields while reducing double-stranded RNA (dsRNA) contamination,
 the latter a common byproduct in mRNA production.

&nbsp;&nbsp;&nbsp;&nbsp;· LineaIVT™:
 An integrated system that combines the LineaDNA and LineaRNAP technologies and their respective
 benefits. For mRNA manufacturers, we believe LineaIVT offers reduced dsRNA contamination
 and expedited mRNA drug substance production, among other advantages.

![](tm2523531d1_ex99-1img001.jpg)

**Management Commentary**

"Our operational activities center on repositioning Applied DNA as a single business that is aligned with our proven core competencies, which underpin our commercially available, cell-free DNA and mRNA manufacturing solutions offerings. With operations now right-sized, coupled with active marketing under the LineaRx brand that is now synonymous with synthetically produced DNA, we look forward to delivering value to shareholders," stated Judy Murrah, chairperson, president, and CEO of Applied DNA.

**Recent Corporate and Operational Updates**

***Financial***

&nbsp;&nbsp;&nbsp;&nbsp;· Monthly
 net cash burn from operations in the reported quarter declined approximately 19% on a sequential
 basis and 25% compared to the prior year period due to cost-cutting and optimization initiatives
 implemented in prior quarters. The Company expects a further reduction in the quarter ending
 September 30, 2025, reflecting the implementation of Corporate Actions.

***Customer Acquisition and Repeat Orders***

&nbsp;&nbsp;&nbsp;&nbsp;· Received
 a multi-gram follow-on order for LineaDNA valued at over $600 thousand from a global manufacturer
 of IVDs for use in a cancer diagnostic application.

&nbsp;&nbsp;&nbsp;&nbsp;· Added
 a U.S.-based mRNA contract development manufacturing organization as a customer for LineaDNA
 IVT templates. This customer is also evaluating LineaRNAP.

&nbsp;&nbsp;&nbsp;&nbsp;· Shipped
 multiple LineaDNA sequences to a U.S.-based developer of a novel vaccine delivery system.

&nbsp;&nbsp;&nbsp;&nbsp;· Subsequent
 to quarter-end, sales quotes were provided to a large public biotech and a multinational
 biotech tools company for LineaDNA to be used in gene editing applications.

***Product and Platform Development***

&nbsp;&nbsp;&nbsp;&nbsp;· Launched
 the LineaRx IVT Discovery Kit, which enables potential customers to easily and rapidly evaluate
 the benefits of LineaDNA and LineaIVT performance against conventional mRNA production methods.

&nbsp;&nbsp;&nbsp;&nbsp;· Launched
 industry marketing for LineaRNAP as a standalone product based on recent Company data confirming
 that LineaRNAP can be used in conventional mRNA production workflows to enable higher mRNA
 yields and integrity with reduced dsRNA as compared with conventional wild-type T7 RNAP.
 The Company also continues to market LineaRNAP as a component of its integrated LineaIVT
 solution.

![](tm2523531d1_ex99-1img001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;· Initiated
 ISO 13485 certification, an internationally recognized quality management standard aligned
 with GMP, to enhance customer trust, expand market opportunities, and elevate LineaRx's
 competitive position. The Company expects to be ISO 13485-certified in the first quarter
 of fiscal 2026.

&nbsp;&nbsp;&nbsp;&nbsp;· Participated
 in multiple mRNA-focused conferences to engage potential customers and showcase its platforms'
 capabilities as part of LineaRx's ongoing sales and marketing strategy.

**Third Quarter Fiscal 2025 Financial Highlights**

As part of the Corporate Actions, the Company announced the closure of its MDx Testing Services business segment (Applied DNA Clinical Labs) to focus exclusively on LineaRx. Financial results for the reported and prior periods have been recast to separately report discontinued operations and the results of continuing operations.

In February 2025, the Company announced the wind down of its DNA Tagging and Security Products and Services business segment and continues to terminate business activities in this segment in accordance with customer agreements. Financial results for this segment are included in the results of continuing operations for the reported and prior periods.

Please refer to segment information detailed in the 'Note H – Segment Information' section of the Form 10-Q for the period reported for more information.

On March 13, 2025, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-fifty (1:50) reverse stock split of its common stock, par value $0.001 per share, effective March 14, 2025. On May 29, 2025, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-fifteen (1:15) reverse stock split of its common stock, par value $0.001 per share, effective June 2, 2025. All warrant, option, share, and per share information in this press release gives retroactive effect to these reverse stock splits.

***Summary Financial Results***

·  ***Total revenues:*** $304 thousand compared to $473 thousand in the third quarter of fiscal
 2024.

·  ***Operating loss:*** $3.7 million, compared to an operating loss of $3.3 million in the prior period.

·  ***Adjusted EBITDA:*** Negative $3.9 million, compared to negative $3.2 million in the prior period.

![](tm2523531d1_ex99-1img001.jpg)

·  ***Monthly net cash burn:*** Monthly net cash burn from operations in the reported period was $934
 thousand, compared to $1.15 million in the second quarter of fiscal 2025 and $1.25 million
 in the prior fiscal year period.

·  ***Cash and cash equivalents as of June 30, 2025:*** $4.7 million, which includes $723
 thousand of proceeds from the exercise of Series A warrants received during the reported
 period. Additional proceeds totaling $292 thousand were received subsequent to the reported
 period from the exercise of Series A warrants.

**Information about Non-GAAP Financial Measures**

As used herein, "GAAP" refers to accounting principles generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and presented in accordance with GAAP, this earnings release includes Adjusted EBITDA and monthly net cash burn from operations, which are non-GAAP financial measures as defined in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information presented in accordance with GAAP. We use this non-GAAP financial measure for internal financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons of the performance and results of operations of our core businesses. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the performance of our businesses by excluding non-cash expenses that may not be indicative of our recurring operating results. We believe these non-GAAP financial measures are useful to investors as they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

"EBITDA" - is defined as earnings (loss) before interest expense, income tax expense and depreciation and amortization expense.

"Adjusted EBITDA" - is defined as EBITDA adjusted to exclude (i) stock-based compensation and (ii) other non-cash expenses and non-cash gains/income.

"Monthly net cash burn" - is defined as total monthly cash outflow, including all operating costs, reduced by cash inflow from revenue.

**About Applied DNA Sciences**

Applied DNA Sciences is a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries. Through its majority-owned subsidiary, LineaRx, Inc., the Company is commercializing its LineaDNA™, LineaRNAP™, and LineaIVT™ platforms to enable the manufacture of next-generation nucleic acid-based therapies.

Visit <u>adnas.com</u> for more information. Follow us on <u>X</u> and <u>LinkedIn</u>. Join our <u>mailing list</u>.

![](tm2523531d1_ex99-1img001.jpg)

**Forward-Looking Statements**

The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding its goal to position the Company for long-term growth and value creation and the potential to achieve that goal, including the future success of its LineaDNA, LineaRNAP and LineaIVT technologies. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, unknown future ability to remain compliant with all Nasdaq listing standards, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its technologies, the fact that there has never been therapeutic clinical trial material and/or a commercial drug product produced utilizing its technologies, whether its restructuring will position the Company for future growth potential, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, Forms 10-Q filed on February 13, 2025, May 15, 2025, and August 14, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

**Investor Relations contact<u>:</u>** Sanjay M. Hurry, 917-733-5573, <u>sanjay.hurry@adnas.com</u>

**Web:** www.adnas.com

**X:** APDN

**- Financial Tables Follow -**

![](tm2523531d1_ex99-1img001.jpg)

**APPLIED DNA SCIENCES, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **June 30,** | **September 30,** |
|  | **2025** | **2024** |
|  | **(unaudited)** |  |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $4727677 | $5852363 |
| Accounts receivable, net of allowance for credit losses of $80,423 and $75,000 at June 30, 2025 and September 30, 2024, respectively | 199047 | 328252 |
| Inventories | 338723 | 432725 |
| Prepaid expenses and other current assets | 338447 | 756185 |
| Current assets of discontinued operations | 25008 | 678146 |
| Total current assets | 5628902 | 8047671 |
| Property and equipment, net | 511203 | 458895 |
| Noncurrent assets of discontinued operations | 11264 | 94337 |
| Other assets: |  |  |
| Restricted cash | 750000 | 750000 |
| Intangible assets | 2698975 | 2698975 |
| Operating right of use asset | 334402 | 739162 |
| Total assets | $9934746 | $12789040 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable and accrued liabilities | $1564707 | $1737366 |
| Operating lease liability, current | 334403 | 545912 |
| Deferred revenue | 12285 | 58785 |
| Current liabilities of discontinued operations | 124565 | 56061 |
| Total current liabilities | 2035960 | 2398124 |
| Long term accrued liabilities | 31467 | 31467 |
| Deferred revenue, long term | 194000 | 194000 |
| Operating lease liability, long term |  | 193249 |
| Deferred tax liability, net | 684115 | 684115 |
| Warrants classified as a liability | 1160 | 320000 |
| Total liabilities | 2946702 | 3820955 |
| Commitments and contingencies (Note G) |  |  |
| Applied DNA Sciences, Inc. stockholders' equity: |  |  |
| Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2025 and September 30, 2024 |  |  |
| Series A Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2025 and September 30, 2024 |  |  |
| Series B Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2025 and September 30, 2024 |  |  |
| Common stock, par value $0.001 per share; 200,000,000 shares authorized as of June 30, 2025, and September 30, 2024; 901,500 and 13,755 shares issued and outstanding as of June 30, 2025, and September 30, 2024, respectively | 902 | 14 |
| Additional paid in capital | 381150267 | 318815358 |
| Accumulated deficit | (373888601) | (309672755) |
| Applied DNA Sciences, Inc. stockholders' equity | 7262568 | 9142617 |
| Noncontrolling interest | (274524) | (174532) |
| Total equity | 6988044 | 8968085 |
| Total liabilities and equity | $9934746 | $12789040 |

---

![](tm2523531d1_ex99-1img001.jpg)

**APPLIED DNA SCIENCES, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months Ended June 30,** | **Three months Ended June 30,** | **Nine months Ended June 30,** | **Nine months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenues |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Product revenues | $195262 | $246644 | $1239747 | $947086 |
| &nbsp;&nbsp;&nbsp;Service revenues | 109131 | 226145 | 697759 | 678777 |
| Total revenues | 304393 | 472789 | 1937506 | 1625863 |
| Cost of product revenues | 299263 | 230188 | 930619 | 853034 |
| Gross profit | 5130 | 242601 | 1006887 | 772829 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 2930627 | 2635863 | 8423602 | 8440919 |
| Research and development | 768563 | 913031 | 2632931 | 2762040 |
| Total operating expenses | 3699190 | 3548894 | 11056533 | 11202959 |
| LOSS FROM OPERATIONS | (3694060) | (3306293) | (10049646) | (10430130) |
| Interest income | 40267 | 29688 | 168762 | 33989 |
| Transaction costs allocated to warrant liabilities |  |  |  | (633198) |
| Unrealized gain on change in fair value of warrants classified as a liability | 6410 | 5160000 | 318840 | 9564000 |
| Unrealized loss on change in fair value of warrants classified as a liability - warrant modification |  |  |  | (394000) |
| Loss on issuance of warrants |  |  |  | (1633767) |
| Other expense, net | (531) | (103) | (23778) | (9060) |
| (Loss) income before provision for income taxes | (3647914) | 1883292 | (9585822) | (3502166) |
| Provision for income taxes |  |  |  |  |
| Net (loss) income from continuing operations | $(3647914) | $1883292 | $(9585822) | $(3502166) |
| Net loss from discontinued operations, net of tax | (336195) | (33791) | (403120) | (272397) |
| NET (LOSS) INCOME | $(3984109) | $1849501 | $(9988942) | $(3774563) |
| Less: Net loss attributable to noncontrolling interest | 38746 | 30295 | 99992 | 78785 |
| NET (LOSS) INCOME attributable to Applied DNA Sciences, Inc. | $(3945363) | $1879796 | $(9888950) | $(3695778) |
| Deemed dividend related to warrant modifications | (15500244) |  | (54326896) | (233087) |
| NET (LOSS) INCOME attributable to common stockholders | $(19445607) | $1879796 | $(64215846) | $(3928865) |
| Net (loss) income per share attributable to common stockholders-basic and diluted from continuing operations | $(33.41) | $1191.52 | $(255.14) | $(4862.32) |
| Net loss per share attributable to common stockholders-basic and diluted from discontinued operations | (0.59) | (21.04) | (1.61) | (362.23) |
| Net (loss) income per share attributable to common stockholders-basic and diluted | $(34.00) | $1170.48 | $(256.75) | $(5224.55) |
| Weighted average shares outstanding- basic and diluted | 572018 | 1606 | 250107 | 752 |

---

![](tm2523531d1_ex99-1img001.jpg)

**APPLIED DNA SCIENCES, INC.**

**CALCULATION AND RECONCILIATION OF ADJUSTED EBITDA**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | Three-Month Period Ended June 30, | Three-Month Period Ended June 30, |
|  | 2025 | 2024 |
| Net loss | $(3984109) | $1849501 |
| Interest income | (40267) | (29688) |
| Depreciation and amortization | 78346 | 134163 |
| Stock-based compensation expense | 24889 | 30336 |
| Unrealized (loss) on change in fair value of warrants classified as a liability | (6410) | (5160000) |
| Total non-cash items | 56558 | (5025189) |
| Consolidated Adjusted EBITDA (loss) | $(3927551) | $(3175688) |

---

###